Pharmaceutical giant Pfizer has announced the appointment of a new executive to its leadership team. Patrizia Cavazzoni, who previously held a prominent position at the Food and Drug Administration (FDA), will take on the role of chief medical officer. In this capacity, she will oversee key operations related to regulatory affairs, pharmacovigilance, and drug safety. Her expertise is expected to enhance Pfizer's interactions with global health authorities and ensure rigorous monitoring of medication safety.

Cavazzoni brings extensive experience in drug evaluation and research to her new role. Prior to joining Pfizer, she served as the head of the FDA’s Center for Drug Evaluation and Research (CDER) from 2020 until early this year. During her tenure, she played a crucial role in shaping policies and overseeing the review process for new drugs. Before her time at the FDA, Cavazzoni had already worked at Pfizer, serving as deputy director for operations. This background positions her well to integrate seamlessly into her new responsibilities, reporting directly to Chris Boshoff, the company’s chief scientific officer.

With Cavazzoni's leadership, Pfizer aims to strengthen its commitment to medical innovation and patient safety. Her appointment underscores the company's dedication to maintaining high standards in pharmaceutical development and regulation. By leveraging her deep understanding of both regulatory frameworks and industry practices, Cavazzoni is poised to drive forward initiatives that promote public health and advance medical knowledge.